News

INNO-406 is being evaluated for the treatment of patients with chronic myeloid leukemia (CML) and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+) and

Mr Gerstel, who has served as chairman of Compugen since 1997, will succeed current president and CEO Alex Kotzer, who recently informed the board of his interest to

This Phase II trial is a prospective, multicenter, investigator-blinded, randomized study which is designed to evaluate the efficacy, safety, and tolerability of NXL104/ceftazidime versus imipenem cilastatin (Primaxin or

Zahed Subhan, CEO of Marillion Pharmaceuticals, said: “177Lu-AMBA is a targeted radiotherapeutic that utilizes an innovative receptor-based technology. In contrast to traditional modes of treatment for advanced cancers,

Biovitrum will continue to be the sole producer of drug substance for Wyeth for ReFacto, as well as Xyntha/ReFacto AF, the successor products, and will continue to receive

The inactivated polio vaccine (IPV) doses are provided by MP Chumakov Institute of Poliomyelitis and Virus Encephalitides through a manufacturing agreement with Sanofi Pasteur. The Russian Federation was

The company plans to call for co-development of this product with a marketing partner. Mahesh Patel, president and CEO of Lipocine, said: “Our patented Lip’ral-SSR technology enabled this

In this new analysis, dronedarone significantly reduced the total number of hospital days by 28% (p

Sanofi Pasteur’s ActHIB vaccine (Haemophilus influenzae type b conjugate vaccine) is marketed in Japan by Daiichi-Sankyo Co and will be available starting December 19, 2008. Wayne Pisano, president